Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing

BACKGROUND: Incidence of Chronic Myeloid Leukemia (CML) is continuously increasing and expected to reach 100,000 patients every year by 2030. Though the discovery of Imatinib Mesylate (IM) has brought a paradigm shift in CML treatment, 20% patients show resistance to this tyrosine kinase inhibiter (...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokeen, Yogender, Sharma, Neeta Raj, Vats, Abhishek, Taneja, Vibha, Minhas, Sachin, Jauhri, Mayank, Sankaran, Satish, Aggarwal, Shyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research and Publications Office of Jimma University 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016334/
https://www.ncbi.nlm.nih.gov/pubmed/29983511
http://dx.doi.org/10.4314/ejhs.v28i2.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016334/
https://www.ncbi.nlm.nih.gov/pubmed/29983511
http://dx.doi.org/10.4314/ejhs.v28i2.5

Ejemplares similares